GeneTex
United States (US)

IGFBP5 recombinant protein

Cat No. GTX65125

Application ELISA, Functional Assay, Apuri, Blocking
Reactivity Human
Species Human
APPLICATION

Application Note

The ED50 as determined by its ability to inhibit IGF-II induced proliferation of MCF-7 is <0.3 mg/ml, in the presence of 15 ng/ml of human IGF-II.

Calculated MW

28. 6 kDa. ( Note )
PROPERTIES

Form

Lyophilized powder

Buffer

10 mM Sodium Citrate solution, pH 3.0.

Storage

Reconstitute in water to a concentration of 0.1-1.0 mg/ml. The solution can then be diluted into other aqueous buffers and store at 4ºC for 1 week or –20ºC for future use.

Antigen Species

Human

Expression System

E. coli

Purification


Purity was assessed by SDS-PAGE (≥98%) and by HPLC (≥98%).

Note

For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TARGET

Synonyms

Insulin-like Growth Factor-Binding Protein5

Background

Human IGF-BP5 is a 28.6 kDa cysteine-rich secreted protein produced by Vascular smooth muscle cells. It is the major IGF-binding protein present in bone tissue and helps potentiate the action of IGF-I on smooth muscle cells, fibroblasts or osteoblasts. Studies show that IGF-BP5 acts as a growth inhibitor and pro-apoptotic agent in breast cancer cells. IGF-BP5 overexpressing mice show an increase in neonatal mortality, reduced female fertility, whole body growth inhibition, and retarded muscle development. Recombinant human IGF-BP5 is a 28.6 kDa protein consisting of 253 amino acid residues.

Research Area

Package List Price ($)
$ 259